Mablink Bioscience, a Lyon, France-based company developing antibody-drug conjugates (ADC), completed a €4M seed financing round.
The round was led by Elaia Partners with participation from Pertinence Invest 2 (Sofimac Innovation advised by Mérieux Equity Partners), Sham Innovation Santé (advised by Turenne Capital), Fondation Fournier-Majoie, Simba Santé (Angelor) and Crédit Agricole Création.
Led by Jean-Guillaume Lafay, CEO, Mablink Bioscience is a biopharmaceutical company which has developed PSARlink™, an innovative and hydrophilic drug-linker technology that brings improved pharmacological properties to antibody-drug conjugates.
The company will use the proceeds of this financing to move forward its ADC pipeline.
FinSMEs
27/04/2021